Samuel Ahuno

Samuel Ahuno


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2016 in Infectious Diseases of Poverty
Verified
Journal Article
Open access
PDF file
AKAlexander Kwarteng
Alexander Kwarteng
SASamuel Ahuno
Samuel Ahuno
FAFreda Osei Akoto
Freda Osei Akoto
There is compelling evidence that not only do anti-filarials significantly reduce larval forms, but that host immune responses also contribute to the clearance of filarial parasites; however, the underlying mechanisms have not been fully elucidated. Filarial infections caused by Wuchereria bancrofti and Brugia species (lymphatic filariasis) and Onchocerca volvulus (onchocerciasis) affect almost 200 million individuals worldwide and pose major public health challenges in endemic regions. Indeed, the collective disability-adjusted life years for both infections is 3.3 million. Infections with these thread-like nematodes are chronic and, although most individuals develop a regulated state, a portion develop severe forms of pathology. Mass drug administration (MDA) programmes on endemic populations focus on reducing prevalence of people with microfilariae, the worm's offspring in the blood, to less than 1 %. Although this has been successful in some areas, studies show that MDA will be required for longer than initially conceived. This paper highlights the mode of action of the various antifilarial treatment strategies and role of host immune response.

30 March 2017 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AKAlexander Kwarteng
Alexander Kwarteng
SASamuel Ahuno
Samuel Ahuno

20 May 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AKAlexander Kwarteng
Alexander Kwarteng
YAYarhands Dissou Arthur
Yarhands Dissou Arthur
JYJohn Kanyiri Yamba
John Kanyiri Yamba
ASAugustina Angelina Sylverken
Augustina Angelina Sylverken
PKPriscilla Kini
Priscilla Kini
EOEllis Owusu-Dabo
Ellis Owusu-Dabo
Lymphatic Filariasis (LF) is a vector-borne neglected tropical disease caused by the filarial nematode parasites that can lead to the disfiguring swelling of the limbs (lymphedema or elephantiasis for late stage) and/or genitalia (hydrocele) in men. Growing evidence suggests that not only are filarial lymphedema patients confronted with huge societal stigma and discrimination, but also experience acute filarial attacks accompanied by swelling of the affected part(s), fever, wounds and peeling of the skin of affected limbs(s). However, the extent to which seasonal variation influence filarial attacks among people with lymphedema was highly speculated without empirical evidence and was thus investigated. In light of this, a cross-sectional study where 142 (70.4% females and 29.6% males) lymphedema patients were recruited from 8 established Wuchereria bancrofti endemic communities in the Ahanta West District, Ghana was carried out to investigate the prevalence and seasonal variation (rainy/wet and dry seasons) of acute filarial attacks. Chi-square test was used to test for association between frequency of attacks and seasonality. The STROBE guidelines for reporting cross-sectional studies was adopted. The average lymphedema leg stage was 2.37 and 2.33 for left and right legs, respectively, while mossy lesions, sores and ulcers were observed among 33.1% of patients with late stage disease (elephantiasis). It was found that 97 (68.3%) of the study participants experience filarial attacks during the wet season and 36 (25.4%) reported the incidence of filarial attacks during both seasons (wet and dry) while 9 (6.3%) of the study participants did not experience any attack at all. Findings from the present study show compelling evidence that the frequency and the prevalence of filarial attacks is significantly increased during wet seasons compared to the dry season.

14 July 2017 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
AKAlexander Kwarteng
Alexander Kwarteng
SASamuel Ahuno
Samuel Ahuno
GKGodwin Kwakye-Nuako
Godwin Kwakye-Nuako
Current treatment for HIV-1 largely relies on chemotherapy through the administration of antiretroviral drugs. While the search for anti-HIV-1 vaccine remain elusive, the use of highly active antiretroviral therapies (HAART) have been far-reaching and has changed HIV-1 into a manageable chronic infection. There is compelling evidence, including several side-effects of ARTs, suggesting that eradication of HIV-1 cannot depend solely on antiretrovirals. Gene therapy, an expanding treatment strategy, using RNA interference (RNAi) and programmable nucleases such as meganuclease, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins (CRISPR–Cas9) are transforming the therapeutic landscape of HIV-1. TALENS and ZFNS are structurally similar modular systems, which consist of a FokI endonuclease fused to custom-designed effector proteins but have been largely limited, particularly ZFNs, due to their complexity and cost of protein engineering. However, the newly developed CRISPR–Cas9 system, consists of a single guide RNA (sgRNA), which directs a Cas9 endonuclease to complementary target sites, and serves as a superior alternative to the previous protein-based systems. The techniques have been successfully applied to the development of better HIV-1 models, generation of protective mutations in endogenous/host cells, disruption of HIV-1 genomes and even reactivating latent viruses for better detection and clearance by host immune response. Here, we focus on gene editing-based HIV-1 treatment and research in addition to providing perspectives for refining these techniques.

1 May 2017 in Acta Tropica
Verified
Journal Article
Closed access
AKAlexander Kwarteng
Alexander Kwarteng
JAJohn Humphrey Amuasi
John Humphrey Amuasi
ASAugustina Angelina Sylverken
Augustina Angelina Sylverken
SASamuel Ahuno
Samuel Ahuno
DODavid Opare
David Opare
EOEllis Owusu-Dabo
Ellis Owusu-Dabo

1 May 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
AKAlexander Kwarteng
Alexander Kwarteng
ASAugustina Sylverken
Augustina Sylverken
EAEBENEZER ASIEDU
EBENEZER ASIEDU
SASamuel Ahuno
Samuel Ahuno
Human filarial infections are vector-borne nematode infections, which include lymphatic filariasis, onchocerciasis, loiasis, and mansonella filariasis. With a high prevalence in developing countries, filarial infections are responsible for some of the most debilitating morbidities and a vicious cycle of poverty and disease. Global initiatives set to eradicate these infections include community mass treatments, vector control, provision of care for morbidity, and search for vaccines. However, there are growing challenges associated with mass treatments, vector control, and antifilarial vaccine development. With the emergence of genome editing tools and successful applications in other infectious diseases, the integration of genetic editing techniques in future control strategies for filarial infections would offer the best option for eliminating filarial infections. In this review, we briefly discuss the mechanisms of the three main genetic editing techniques and explore the potential applications of these powerful tools to control filarial infections.